Borderline resectable pancreatic cancer treated by pancreaticoduodenectomy with splenic artery resection (PD-SAR) after neoadjuvant chemotherapy: a case report-Reference-Cited by-同舟云学术

Borderline resectable pancreatic cancer treated by pancreaticoduodenectomy with splenic artery resection (PD-SAR) after neoadjuvant chemotherapy: a case report

Published:2021-04-30 Issue:2 Volume:36 Page:188-194
ISSN:0913-0071
Container-title:Suizo
language:en
Short-container-title:Journal of the Japan Pancreas Society

Author:

TANAKA Hideharu¹,IMAI Hisashi¹,HIGASHI Toshiya¹,MURASE Katsutoshi¹,SUZUI Natsuko²,TANAKA Yoshihiro¹,OKUMURA Naoki¹,MATSUHASHI Nobuhisa¹,TAKAHASHI Takao¹,YOSHIDA Kazuhiro¹

Affiliation:

1. Department of Surgical Oncology, Gifu University Hospital

2. Pathology Division, Gifu University Hospital

Publisher

Japan Pancreas Society

Link

https://www.jstage.jst.go.jp/article/suizo/36/2/36_188/_pdf

Reference19 articles.

1. 1) National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncoloygy. Pancreatic odenocarcinoma. Version2 2018. 2018.

2. 4) Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13: 1035-46.

3. 5) Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2014; 155: 977-88.

4. 6) Adams RB, Allen PJ. Surgical treatment of resectable and borderline resectable pancreatic cancer: expert consensus statement by Evans et al. Ann Surg Oncol 2009; 16: 1745-50.

5. 7) Fujii T, Yamada S, Murotani K, et al. Inverse probability of treatment weighting analysis of upfront surgery versus neoadjuvant chemoradiotherapy followed by surgery for pancreatic adenocarcinoma with arterial abutment. Medicine (Baltimore) 2015; 94: e1647.